Informações:
Falhas:
ID
34599
Descrição
Evaluation of Dapagliflozin Taken Twice-daily; ODM derived from: https://clinicaltrials.gov/show/NCT01217892
Link
https://clinicaltrials.gov/show/NCT01217892
Palavras-chave
Versões (1)
- 19/01/2019 19/01/2019 -
Titular dos direitos
see on clinicaltrials.gov
Transferido a
19 de janeiro de 2019
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Type 2 Diabetes NCT01217892
Eligibility Type 2 Diabetes NCT01217892
- StudyEvent: Eligibility
Similar models
Eligibility Type 2 Diabetes NCT01217892
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
ID.1
Item
provision of informed consent prior to any study specific procedures
boolean
ID.2
Item
diagnosis of t2dm
boolean
ID.3
Item
current antihyperglycaemic treatment with metformin immediate release formulation monotherapy >/= 1500 mg/day at a stable dose for at least 10 weeks prior to enrolment. other treatment with oads within the 10 weeks prior to enrolment is not permitted.
boolean
ID.4
Item
hba1c ≥ 6.7% and ≤10.5%, based on central laboratory values from screening visit, and enrolment visit 1.
boolean
ID.5
Item
diagnosis of type 1 diabetes mellitus, known diagnosis of maturity onset diabetes of the young (mody) or secondary causes of diabetes mellitus
boolean
ID.6
Item
history of diabetic ketoacidosis
boolean
ID.7
Item
symptoms of poorly controlled diabetes including, but not limited to, marked polyuria, polydipsia, and/or greater than 10% weight loss during the 3 months prior to enrolment
boolean
ID.8
Item
fpg >270 mg/dl (>15.0 mmol/l)
boolean
ID.9
Item
bmi >45 kg/m2
boolean